2,3-Diphosphoglyceric acid pentasodium
Based on 1 Customer Validation
2,3-Diphosphoglyceric acid (2,3-DPG) pentasodium is an intermediate metabolite of the 2,3-BPG shunt in erythrocytes, capable of binding to hemoglobin and modulating oxygen affinity. 2,3-Diphosphoglyceric acid pentasodium stabilizes the deoxyhemoglobin T-state conformation, reduces hemoglobin oxygen affinity, and promotes oxygen release in tissues. 2,3-Diphosphoglyceric acid pentasodium inhibits the growth of Plasmodium falciparum within erythrocytes without causing hemolysis or a decrease in ATP levels. 2,3-Diphosphoglyceric acid pentasodium is useful for research related to malaria and Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 1287756-01-7
- Formula: C3H3Na5O10P2
- Molecular Weight:375.95
-
Storage:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
Human Endogenous Metabolite |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
6.40 mM
|
Cytotoxicity against human hepatocellular carcinoma HEPG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human hepatocellular carcinoma HEPG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
35372095 |
In Vitro
2,3-Diphosphoglyceric acid (0.25-16 mM; 0-96 h) pentasodium does not induce hemolysis in healthy human RBCs[2].
2,3-Diphosphoglyceric acid (0.25-16 mM; 48 h) pentasodium exhibits cytotoxicity against HEPG2 cells with an IC50 of 6.40 mM[2].
2,3-Diphosphoglyceric acid (0.25-16 mM; 12-96 h) pentasodium exhibits antimalarial activity against 3D7 P. falciparum, with its IC50 showing time dependence[2].
2,3-Diphosphoglyceric acid (8 mM; 48 h) pentasodium reduces the number of merozoites produced by 3D7 P. falciparum schizonts in human erythrocytes[2].
2,3-Diphosphoglyceric acid (8 mM; 96 h) pentasodium inhibits the invasion and maturation of 3D7 P. falciparum without depleting ATP in human RBCs, whereas pretreatment of RBCs before infection has no effect[2].
2,3-Diphosphoglyceric acid (8 mM) pentasodium does not block the escape or re-invasion of 3D7 P. falciparum from untreated human RBCs[2].
2,3-Diphosphoglyceric acid (8 mM; 30 h) pentasodium shifts the metabolic profile of 3D7 P. falciparum-infected human RBCs closer to that of uninfected RBCs, possibly involving specific metabolites[2].
2,3-Diphosphoglyceric acid (8 mM; 48 h) pentasodium impairs the growth of 3D7 P. falciparum and prevents its normal entry into a new cycle[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1287756-01-7
-
Appearance Oil
-
Molecular Weight 375.95
-
Formula C3H3Na5O10P2
-
Color Colorless to light yellow
-
SMILES
O=C(O[Na])C(OP(O[Na])(O[Na])=O)COP(O[Na])(O[Na])=O
-
Synonyms
2,3-DPG pentasodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Solvent & Solubility
In Vitro:
H2O : ≥ 200 mg/mL (531.99 mM)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Płoszczyca K, et al. Red Blood Cell 2,3-Diphosphoglycerate Decreases in Response to a 30 km Time Trial Under Hypoxia in Cyclists. Frontiers in physiology. 2021;12:670977. [Content Brief]
[2]. Morais I, et al. Synthetic Red Blood Cell-Specific Glycolytic Intermediate 2,3-Diphosphoglycerate (2,3-DPG) Inhibits Plasmodium falciparum Development In Vitro. Front Cell Infect Microbiol. 2022 Mar 15;12:840968. [Content Brief]
[3]. Kosenko EA, et al. Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease. CNS & neurological disorders drug targets. 2016;15(1):113-23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.6599 mL | 13.2996 mL | 26.5993 mL | 66.4982 mL |
| 5 mM | 0.5320 mL | 2.6599 mL | 5.3199 mL | 13.2996 mL | |
| 10 mM | 0.2660 mL | 1.3300 mL | 2.6599 mL | 6.6498 mL | |
| 15 mM | 0.1773 mL | 0.8866 mL | 1.7733 mL | 4.4332 mL | |
| 20 mM | 0.1330 mL | 0.6650 mL | 1.3300 mL | 3.3249 mL | |
| 25 mM | 0.1064 mL | 0.5320 mL | 1.0640 mL | 2.6599 mL | |
| 30 mM | 0.0887 mL | 0.4433 mL | 0.8866 mL | 2.2166 mL | |
| 40 mM | 0.0665 mL | 0.3325 mL | 0.6650 mL | 1.6625 mL | |
| 50 mM | 0.0532 mL | 0.2660 mL | 0.5320 mL | 1.3300 mL | |
| 60 mM | 0.0443 mL | 0.2217 mL | 0.4433 mL | 1.1083 mL | |
| 80 mM | 0.0332 mL | 0.1662 mL | 0.3325 mL | 0.8312 mL | |
| 100 mM | 0.0266 mL | 0.1330 mL | 0.2660 mL | 0.6650 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
2,3-Diphosphoglyceric acid pentasodium Related Classifications
HY-113050A Related Classifications
Powered by Bioz
Keywords
- 2,3-Diphosphoglyceric acid pentasodium
- 1287756-01-7
- 2,3-DPG pentasodium
- Endogenous Metabolite
- Parasite
- parasite growth and maturation
- merozoite progeny
- oxygen dissociation curve
- Luebering-Rapoport pathway
- T-state conformation of hemoglobin
- 3D7 P. falciparum
- hemoglobin oxygen affinity
- glycolytic intermediate metabolite
- HEPG2 cells
- hemoglobin-binding modulator
- Inhibitor
- inhibitor
- inhibit